Drug Search Results
More Filters [+]

BMS-986463

Alternative Names: BMS-986463, BMS 986463, BMS986463
Latest Update: 2024-08-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: N/A

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-986463

Countries in Clinic: Canada, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Non-Small-Cell Lung Cancer|Ovarian Cancer|Serous Cystadenocarcinoma|Uterine Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CA231-0000

P1

Recruiting

Uterine Cancer|Serous Cystadenocarcinoma|Ovarian Cancer|Non-Small-Cell Lung Cancer

2028-12-19

Recent News Events

Date

Type

Title